Adapting well known chromatographic techniques for the analysis of biomolecules

Register & watch

Thursday, June 18, 2020
15:00 to 16:00 CEST (Berlin, Paris, Madrid)

Regulatory guidelines (ICH Q6B) state that a detailed characterisation of all therapeutic biomolecules is carried out prior to any new product launch. It is important to confirm primary structure and identify any post translational modifications (PTMs) which have occurred during manufacturing processes. When considering biosimilars or biobetters, a comparison should be made with the Originator therapeutic.

Chromatography is a well established technique for the analysis of small molecule therapeutics, their related substances and stability, and is useful for both quantitation and quality purposes. In this webinar we discuss how you can draw from experience with small molecule method development to optimise biomolecule methodologies. We also discuss how ion-pair reagents can be added to the mobile phase to enhance the interaction of more polar biomolecules like oligonucleotides, and lead to excellent separations even to the n+/-1 level. Whether you are working with peptides or proteins, this webinar aims to provide ideas on how to approach your analysis using well understood and recognised modes of chromatography.

Register & watch

Presented by:

Gemma Lo

Gemma Lo is a key part of the business development team at Avantor, and is responsible for leading a wide range of HPLC and UHPLC training events and seminars across Europe.

Gemma has over a decade of experience working in the technical support team, troubleshooting chromatography methods, recommending suitable column chemistries, and supporting the vast range of HPLC and UHPLC columns in the portfolio. Originally a Biochemist, her focus areas include the analysis of biomolecules by various chromatographic techniques, and the analysis of polar analytes.

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.